Simplexia is a collaboration project between University of Gothenburg and Chalmers University of Technology, developing a vaccine against herpes simplex virus type 2 (HSV-2) infection. HSV-2 is the most common sexually transmitted infection in the world and the infection causes genital herpes with painful and recurrent genital blisters. The virus can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.